scholarly journals Nutritional support improves antibody response to influenza virus vaccine in the elderly.

BMJ ◽  
1985 ◽  
Vol 291 (6505) ◽  
pp. 1348-1349 ◽  
Author(s):  
M Chavance ◽  
B Herbeth ◽  
T Mikstacki ◽  
C Fournier ◽  
G Vernhes ◽  
...  
1955 ◽  
Vol 1 (4) ◽  
pp. 249-255
Author(s):  
Barbara K. Buchner ◽  
D. B. W. Reid ◽  
G. Dempster

The antibody response to the subcutaneous inoculation of a single 1 ml. dose of a quadrivalent formalin-killed influenza virus egg vaccine has been measured. The vaccine used contained two A prime components and an A and a B component. Satisfactory responses were obtained two weeks after inoculation to the A and B components and to one of the A prime strains (FM1). A poor antibody response was noted to the other A prime strain incorporated in the vaccine (FW50). The highest levels were obtained with the Lee strain (Type B) which also stimulated an antibody rise to a recently isolated Type B strain. Antibody levels were maintained for at least 12 weeks. Treatment of the sera with RDE was found to influence the results obtained with the FM1 strain used.


1981 ◽  
Vol 86 (1) ◽  
pp. 1-16 ◽  
Author(s):  
R. Jennings ◽  
C. W. Potter ◽  
P. M. O. Massey ◽  
B. I. Duerden ◽  
J. Martin ◽  
...  

SUMMARYThree different types of bivalent influenza virus vaccine, a whole virus, an aqueous-surface-antigen vaccine and an adsorbed-surface-antigen vaccine were tested at three dosage levels in volunteers primed with respect to only one of the haemagglutinin antigens present in the vaccines.The local and systemic reactions to all three vaccine types were mild in nature and, following first immunization, the aqueous-surface-antigen vaccine was the least reactogenic. The serum haemagglutination-inhibiting antibody response to the A/Victoria/75 component of the vaccines, to which the volunteer population was primed, was greatest following immunization with the aqueous-surface-antigen vaccine; the greatest antibody response to the A/New Jersey/76 component of the vaccines was observed following immunization with whole virus vaccine.


PEDIATRICS ◽  
1959 ◽  
Vol 23 (1) ◽  
pp. 54-62
Author(s):  
Calvin M. Kunin ◽  
Robert Schwartz ◽  
Sumner Yaffe ◽  
John Knapp ◽  
Francis X. Fellers ◽  
...  

Polyvalent influenza-virus vaccine was administered to 55 children; 44 of these children were in various stages of nephrotic syndrome, including 17 under treatment with adrenocortical hormones; 5 were children with the adrenogenital syndrome receiving replacement cortisone therapy, and 6 were normal controls. Antibody response, as measured by the hemagglutination-inhibition test 2 weeks following a single subcutaneous dose of vaccine, was not significantly different in children with active or inactive disease, and appeared to be similar in those receiving hormone therapy and in those who were not. The serum levels of gamma-globulin were lower in children with active nephrotic syndrome, but this did not affect either the prevaccination levels of influenza A prime antibody or the response to the vaccine. No change in the status of activity of nephrosis occurred during the period of immunization or immediately thereafter, even in patients who had moderate febrile reactions to the vaccine. The failure of any of the groups to respond serologically to the Asian strain component of the vaccine is discussed.


2003 ◽  
Vol 77 (9) ◽  
pp. 5218-5225 ◽  
Author(s):  
Mimi Guebre-Xabier ◽  
Scott A. Hammond ◽  
Diane E. Epperson ◽  
Jianmei Yu ◽  
Larry Ellingsworth ◽  
...  

ABSTRACT Vaccine strategies, such as influenza virus vaccination of the elderly, are highly effective at preventing disease but provide protection for only the responding portion of the vaccinees. Adjuvants improve the magnitude and rates of responses, but their potency must be attenuated to minimize side effects. Topical delivery of strong adjuvants such as heat-labile enterotoxin from Escherichia coli (LT) induces potent immune responses. We hypothesized that LT delivered alone in an immunostimulating (LT-IS) patch placed on the skin at the site of injection could augment the immune response to injected vaccines. This was based on the observation that topically applied LT induces migration of activated antigen-presenting cells (APCs) from the skin to the proximal draining lymph node (DLN), and that APCs loaded with antigen by injection in the same anatomical region also migrate to the same DLN. We observed that when influenza virus vaccine is injected and an LT-IS patch is placed to target the same DLN, the influenza virus antibody response is enhanced. Similarly, influenza virus-specific T cells isolated from the lungs show increased levels of gamma interferon and interleukin-4 production. An LT-IS patch placed near an injected vaccine also leads to increased levels of hemagglutination inhibition titers, enhanced mucosal immunoglobulin A responses, and enhanced antigen presentation. Although the mechanisms by which an LT-IS patch exerts its enhancing effects need further study, the enhanced immune responses, ability to safely use potent adjuvants, and simplicity of LT-IS patch application address an important unmet need and provide a new immune enhancement strategy.


Sign in / Sign up

Export Citation Format

Share Document